Class / Patent application number | Description | Number of patent applications / Date published |
562507000 | Alicyclic acids having an element other than oxygen, carbon, or hydrogen | 17 |
20080207945 | Preparation of gabapentin by liquid-liquid extraction - This invention relates to an efficient process for converting gabapentin hydrochloride salt to gabapentin by liquid-liquid extraction using a counter-current extraction method. | 08-28-2008 |
20080262264 | Process For the Preparation of Sulfomate-Carboxylate Derivatives - Disclosed is a process for the preparation of Compound (III), salt or solvate thereof by reacting Compound (I), salt or solvate thereof with Compound (II) in a toluene solvent in the presence of an additive such as water or an alcohol. Also disclosed is a process for the preparation of Compound (IV) comprising hydrolyzing the obtained Compound (III) if necessary, and then oxidizing. | 10-23-2008 |
20080269517 | PROCESS FOR THE PREPARATION OF ACID HALIDES - A process for the preparation of acid halides of formula I | 10-30-2008 |
20090043126 | Process and Methods for the Preparation of Gabapentin and Its Intermediates - The invention provides a process for preparing gabapentin and its intermediates. The process generally involves treating gabapentin lactam with an aqueous solution of hydrobromic acid to yield gabapentin hydrobromide salt as an intermediate, which can be isolated by filtration. The gabapentin hydrobromide salt can then be hydrolyzed with a base, such as an organic amine, to yield gabapentin that can be isolated by filtration. | 02-12-2009 |
20090203936 | SYNTHESIS OF 3-(5-NITROCYCLOHEX-1-ENYL) ACRYLIC ACID AND ESTERS THEREOF - This application discloses provides a process for the introduction of nitro-group functionality into a compound which contains also a site of unsaturation and/or oxygen functionality by direct (one step) oxidation of an oxime functional group mediated by a molybdenum VI/VII peroxo complex, the process comprising:
| 08-13-2009 |
20090292138 | PROCESS FOR THE PURIFICATION OF GABAPENTIN - The present invention relates to a process for the purification of gabapentin. The process relates to the addition of hydrochloric acid to an aqueous solution or suspension of gabapentin, before, during or after the concentration step of that solution, and the subsequent slurry of the gabapentin by the addition of an alcoholic solvent. The so obtained gabapentin has an high purity degree and, in particular, is characterized by a low content of lactam. | 11-26-2009 |
20090326266 | PROCESS FOR THE PREPARATION OF GABAPENTIN - A process for the preparation of 1,1-cyclohexanediacetic acid monoamide comprising the amination of 1,1-cyclohexanediacetic acid anhydride by reaction with aqueous NH | 12-31-2009 |
20100004485 | GABAPENTIN ENACARBIL SALTS AND PROCESSES FOR THEIR PREPARATION - The preparation and use of calcium, barium, magnesium and copper salts of gabapentin enacarbil are described. | 01-07-2010 |
20100029983 | PROCESS FOR PREPARING GABAPENTIN - A process for preparing gabapentin of formula 1, which comprises Formula (I) converting 1-allyl-cyclohexanecarboxaldehyde into 1-allyl-cyclohexanecarbonitrile; ozonizing 1-allyl-cyclohexanecarbonitrile to obtain 1-cyano-cyclohexaneacetaldehyde; acetalizing 1-cyano-cyclohexaneacetaldehyde with a suitable acetalizing agent to give the corresponding acetal and converting the latter into gabapentin. | 02-04-2010 |
20100056826 | RADIOACTIVE DIAGNOSTIC IMAGING AGENT - A composition comprising a radioactive fluorine-labeled amino acid compound, which is reduced in radiolysis, is provided. A composition is produced by mixing the radioactive fluorine-labeled amino acid compound with a sugar lactone in an amount effective to prevent the radiolysis As the sugar lactone, one selected from the group consisting of ascorbic acid and glucono-σ-lactone can preferably be used. The sugar lactone is preferably one selected from the compounds that are acceptable as pharmaceutical additives. The composition preferably contains the sugar lactone in an amount not less than 0.5 μmol/mL and not more than an amount acceptable for pharmaceutical additives. Preferably, the composition is prepared to have a radioactive concentration in use of 25-125 MBq/mL. | 03-04-2010 |
20100137636 | IDENTIFICATION OF A NITRILASE FROM B. JAPONICUM BY RATIONAL GENOME MINING AND METHODS OF USE - The present disclosure relates to methods of rational genome mining. A method may include narrowing the number of clones that would otherwise need to be screened and/or identifying a gene with a desired catalytic activity. The disclosure also relates to a nitrile hydrolase from | 06-03-2010 |
20100168470 | Process for preparing alicyclic carboxylic acid compounds - A process for preparing at least one alicyclic carboxylic acid compound by Grignard reaction, the process comprising:
| 07-01-2010 |
20100197962 | Use of Neboglamine in the Treatment of Toxicodependency - Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine. | 08-05-2010 |
20110152573 | PROCESS FOR PRODUCING N-PROTECTED AMINO ACID - The present invention relates to a method for producing N-protected amino acid. Specifically, the present invention provides a method in which a protecting group is introduced to the amino group of an amino acid in a reaction under alkaline condition, and the N-protected amino acid thus generated is then separated from the reaction solution as crystals, without undergoing an extraction step or a concentration step. The present inventors have completed the invention based on the finding that desirable crystals of N-protected amino acids may be obtained without extraction, concentration or recrystallization steps between the initial generation of the N-protected amino acid molecules and the subsequent separation of the crystals, by first adding an water-soluble organic solvent and optionally water to the reaction solution (alkaline) containing the N-protected amino acid, and then neutralizing the solution by an acid. | 06-23-2011 |
20110306787 | PROCESS FOR THE PREPARATION OF GABAPENTIN - This invention discloses a process for converting gabapentin acid salt to free gabapentin, where the salt is dissolved in an organic solvent in which both gabapentin acid salt and free gabapentin are soluble. The solution is treated with a powdered alkaline base to liberate free gabapentin which will remain in solution. The insoluble alkali salt of the acid is removed by filtration. From the filtrate free gabapentin is obtained either by adding anti-solvent or by extraction with water. | 12-15-2011 |
20120010428 | PROCESS FOR THE PREPARATION OF SULFOMATE-CARBOXYLATE DERIVATIVES - Disclosed is a process for the preparation of Compound (III), salt or solvate thereof by reacting Compound (I), salt or solvate thereof with Compound (II) in a toluene solvent in the presence of an additive such as water or an alcohol. Also disclosed is a process for the preparation of Compound (IV) comprising hydrolyzing the obtained Compound (III) if necessary, and then oxidizing. | 01-12-2012 |
20120065426 | PROCESS FOR PREPARING AMINE COMPOUND - The present invention aims to provide a practical process for preparing amine compounds through a generalized highly-diastereoselective reductive amination reaction. The present invention relates to a process for diastereoselectively preparing an amine compound using a catalyst employed in a reductive amination reaction, comprising a specific organometallic compound represented by the following general formula (1): | 03-15-2012 |